EP2780082A4 - Compositions and methods for treating alzheimer's disease - Google Patents

Compositions and methods for treating alzheimer's disease

Info

Publication number
EP2780082A4
EP2780082A4 EP12847618.1A EP12847618A EP2780082A4 EP 2780082 A4 EP2780082 A4 EP 2780082A4 EP 12847618 A EP12847618 A EP 12847618A EP 2780082 A4 EP2780082 A4 EP 2780082A4
Authority
EP
European Patent Office
Prior art keywords
disease
compositions
methods
treating alzheimer
alzheimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12847618.1A
Other languages
German (de)
French (fr)
Other versions
EP2780082A1 (en
Inventor
Neil R Cashman
Grant Mcclarty
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
CNJ Holdings Inc
Original Assignee
University of British Columbia
Cangene US Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia, Cangene US Inc filed Critical University of British Columbia
Publication of EP2780082A1 publication Critical patent/EP2780082A1/en
Publication of EP2780082A4 publication Critical patent/EP2780082A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Psychiatry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
EP12847618.1A 2011-11-10 2012-11-12 Compositions and methods for treating alzheimer's disease Withdrawn EP2780082A4 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161558430P 2011-11-10 2011-11-10
US201261589809P 2012-01-23 2012-01-23
US201213582308A 2012-08-31 2012-08-31
PCT/US2012/064722 WO2013071267A1 (en) 2011-11-10 2012-11-12 Compositions and methods for treating alzheimer's disease

Publications (2)

Publication Number Publication Date
EP2780082A1 EP2780082A1 (en) 2014-09-24
EP2780082A4 true EP2780082A4 (en) 2015-08-05

Family

ID=48290671

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12847618.1A Withdrawn EP2780082A4 (en) 2011-11-10 2012-11-12 Compositions and methods for treating alzheimer's disease

Country Status (8)

Country Link
EP (1) EP2780082A4 (en)
CN (1) CN104093454A (en)
AU (1) AU2012335014A1 (en)
CA (1) CA2855669A1 (en)
EA (1) EA201491851A1 (en)
HK (1) HK1201771A1 (en)
SG (1) SG11201403272YA (en)
WO (1) WO2013071267A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011106885A1 (en) 2010-03-03 2011-09-09 The University Of British Columbia Oligomer-specific amyloid beta epitope and antibodies
EP3102611A4 (en) * 2014-02-03 2017-08-23 Cangene Corporation Humanized beta-amyloid binding molecules and uses thereof
WO2016008047A1 (en) * 2014-07-14 2016-01-21 Cangene Corporation Cyclic peptide vaccination for treatment of amyloid beta-related disorders
JP2018516901A (en) * 2015-05-18 2018-06-28 シナプテック・ディヴェロップメント・エルエルシーＳｙｎａｐｔｅｃ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｌｃ Galantamine clearance of amyloid β
KR20180094876A (en) 2015-11-09 2018-08-24 더 유니버시티 오브 브리티쉬 콜롬비아 Amyloid beta epitopes and antibodies thereto
KR20180088828A (en) * 2015-11-09 2018-08-07 더 유니버시티 오브 브리티쉬 콜롬비아 N-terminal epitopes in amyloid beta and morphologically-selective antibodies thereto
CN108350052A (en) * 2015-11-09 2018-07-31 英属哥伦比亚大学 Epitope in amyloid beta intermediate region and its conformation antibodies selective
CA3004493A1 (en) * 2015-11-09 2017-05-18 The University Of British Columiba C-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
CA3004496A1 (en) * 2015-11-09 2017-05-18 Neil R. Cashman Epitopes in amyloid beta and conformationally-selective antibodies thereto
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
CN112661828B (en) * 2021-01-15 2022-04-01 武汉大学 Antigen peptide of synapsin, antibody and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010002251A1 (en) * 2008-07-01 2010-01-07 De Staat Der Nederlanden, Vert. Door De Minister Van Vws Vaccine against amyloid folding intermediate
WO2011106885A1 (en) * 2010-03-03 2011-09-09 The University Of British Columbia Oligomer-specific amyloid beta epitope and antibodies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2379504A2 (en) * 2008-12-22 2011-10-26 Sloan Kettering Institute For Cancer Research Coumarin-based compounds
US20120309028A1 (en) * 2010-02-09 2012-12-06 Bristol-Myers Squibb Company Immunoassay standards and measurement of clinical biomarkers using intra-assay calibration standards

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010002251A1 (en) * 2008-07-01 2010-01-07 De Staat Der Nederlanden, Vert. Door De Minister Van Vws Vaccine against amyloid folding intermediate
WO2011106885A1 (en) * 2010-03-03 2011-09-09 The University Of British Columbia Oligomer-specific amyloid beta epitope and antibodies

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BRIAN O'NUALLAIN ET AL: "Human Plasma Contains Cross-Reactive A[beta] Conformer-Specific IgG Antibodies +", BIOCHEMISTRY, vol. 47, no. 47, 25 November 2008 (2008-11-25), pages 12254 - 12256, XP055198127, ISSN: 0006-2960, DOI: 10.1021/bi801767k *
MAGGA JOHANNA ET AL: "Human intravenous immunoglobulin provides protection against AÎ toxicity by multiple mechanisms in a mouse model of Alzheimer's disease", JOURNAL OF NEUROINFLAMMATION, BIOMED CENTRAL LTD., LONDON, GB, vol. 7, no. 1, 7 December 2010 (2010-12-07), pages 90, XP021089590, ISSN: 1742-2094, DOI: 10.1186/1742-2094-7-90 *
MICHELA ROSINI ET AL: "Inhibition of Acetylcholinesterase, [beta]-Amyloid Aggregation, and NMDA Receptors in Alzheimer's Disease: A Promising Direction for the Multi-target-Directed Ligands Gold Rush", JOURNAL OF MEDICINAL CHEMISTRY, vol. 51, no. 15, 1 August 2008 (2008-08-01), pages 4381 - 4384, XP055198095, ISSN: 0022-2623, DOI: 10.1021/jm800577j *
See also references of WO2013071267A1 *

Also Published As

Publication number Publication date
EP2780082A1 (en) 2014-09-24
CA2855669A1 (en) 2013-05-16
AU2012335014A1 (en) 2014-06-19
WO2013071267A1 (en) 2013-05-16
SG11201403272YA (en) 2014-08-28
EA201491851A1 (en) 2015-12-30
CN104093454A (en) 2014-10-08
HK1201771A1 (en) 2015-09-11

Similar Documents

Publication Publication Date Title
EP2707369A4 (en) Compositions and methods for treating alzheimer's disease
HRP20182069T1 (en) Pharmaceutical compositions for treating alzheimer's disease
ZA201406209B (en) Methods and compositions for treating huntington's disease
SG11201403272YA (en) Compositions and methods for treating alzheimer's disease
HK1202416A1 (en) Compositions and methods for preventing and treating oral diseases
IL236054A0 (en) Compositions and methods for treating crohn's disease and related conditions and infections
EP2684167A4 (en) Compositions and methods useful for treating diseases
EP2655334A4 (en) Compositions and methods useful for treating diseases
HK1246660A1 (en) Methods and drug products for treating alzheimer's disease
EP2542255A4 (en) Methods and compositions for treating degos' disease
DK3292875T3 (en) Compositions and methods for treating diseases
EP2691529A4 (en) Methods and compositions for treating brain diseases
EP2485733A4 (en) Methods for treating alzheimer's disease
HRP20180687T1 (en) Compositions and methods for treating celiac sprue disease
HK1202248A1 (en) Compositions and methods for treating neurodegenerative disease
HK1202246A1 (en) Compositions and methods for treating neurodegenerative disease
EP2866894A4 (en) Compositions and methods of treating alzheimer's disease
EP2667896A4 (en) Methods and compositions for treating alzheimer's disease
EP2906225A4 (en) Methods of treating kennedy's disease
EP2693877A4 (en) Methods and compositions for treating raynaud's disease
EP2829605A4 (en) Method for screening therapeutic and/or prophylactic agents for alzheimer's disease
ZA201402477B (en) Compounds for use in the treatment of alzheimer's disease
IL214340A0 (en) Methods and compositions for treating alzheimer's disease
EP2892618A4 (en) Method for selectively inhibiting the activity of acat1 in the treatment of alzheimer's disease

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140602

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20150703

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/68 20060101ALI20150629BHEP

Ipc: C07K 16/06 20060101AFI20150629BHEP

Ipc: C07K 14/47 20060101ALI20150629BHEP

Ipc: A61K 39/395 20060101ALI20150629BHEP

Ipc: C07K 7/64 20060101ALI20150629BHEP

Ipc: A61P 25/28 20060101ALI20150629BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1201771

Country of ref document: HK

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MCCLARTY, GRANT

Owner name: CANGENE U.S. INCORPORATED

Owner name: THE UNIVERSITY OF BRITISH COLUMBIA

Owner name: CASHMAN, NEIL R.

Owner name: CANGENE CORPORATION

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CNJ HOLDINGS INC.

Owner name: THE UNIVERSITY OF BRITISH COLUMBIA

17Q First examination report despatched

Effective date: 20170811

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20171222

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1201771

Country of ref document: HK